PFE News and Press, Pfizer Inc. From 06/14/24

2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...

2024-06-14 08:49:30 ET More on Pfizer Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates Will Boost Re...

Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (e...

2024-06-13 18:34:04 ET More on BioNTech, Moderna, etc. BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcar...

2024-06-13 09:00:00 ET U.S. stock index futures on Thursday were mixed . Wall Street's benchmark and tech-heavy gauges were on track to extend their gains from the previous session, but its blue-chip average looked set to add onto losses. Here are some stocks to watch on Thursday: ...

2024-06-13 09:00:00 ET Summary The markets had a strong week, with the S&P 500 gaining 0.97% and the Dow Jones Industrial Average gaining 1.6%. Yields on the 10-year Treasury shot up to 4.9% ahead of the FOMC meeting. The Dividend Harvesting Portfolio traded sideways but c...

2024-06-13 07:00:26 ET More on Pfizer, Roche, etc. Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates ...

2024-06-13 02:30:42 ET Summary A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street expectations, and the company maintained its full-ye...

2024-06-12 17:02:28 ET More on Pfizer Pfizer: Surging Cancer Rates Will Boost Revenues Pfizer: Too Early For A Turnaround Pfizer, Flagship to collaborate on obesity drug discovery Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Globa...

Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not ...